GENB

Conviction 31HealthcareScan · Thu, Sep 24, 2026

Generate Biomedicines, Inc. (GENB) closed at $15.99 (-3.21%) on Sep 24, 2026. Price is above its 50-day. RSI(14) 49, -21.5% from its 52-week high, +26.4% year to date. Sector: Healthcare · Biotechnology.

GENB$15.99-3.21%

ResistanceSupportVol 14

Vol MA14 1.33M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Generate Biomedicines, Inc.Biotechnologywww.generatebiomedicines.com ↗

Price15.99

Change-3.21%

Gap-1.15%

Rel volume1.52×

Avg volume1.42M

Avg $ vol22.87M

SMA 2016.16

SMA 5015.37

SMA 200—

Price vs 50+4.02%

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 19.13

RSI (14)49

MACD hist-0.01

MACD crossbear · 0d

Stoch %K / %D33 / 55

ADX (14)32

+DI / −DI27 / 21

RSI divergence—

MACD divergence—

ATR %6.96%

ADR %6.10%

52w high20.38

52w low11.21

From 52w high-21.54%

Above 52w low+42.64%

New 52w highNo

SqueezeOn · 2d

Bollinger width16.24%

%B0.44

Donchian pos38.63%

Donchian high17.97

Donchian low14.74

AVWAP (52w high)16.83

vs AVWAP high-5.01%

AVWAP (52w low)15.07

vs AVWAP low+6.11%

OBV trendFlat

Chaikin MF (20)-0.10

Today vs 20d1.52×

Avg vol (14d)1.33M

Avg vol (20d)1.42M

Avg $ vol (20d)22.87M

Market cap2.05B

RS Rating—

RS 3m (vs SPY)-7.11%

RS 6m (vs SPY)+18.35%

RS line new highNo

Trend template—

Technical rank72.9

1 week-6.60%

1 month-21.54%

3 months-2.62%

6 months+35.16%

1 year—

YTD+26.40%

P/E—

P/B4.50

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current8.30

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target25.33

Target upside58.41%

Analyst ratingBuy

Institutional77.29%

Ent. value1.92B

Revenue6.31M

Net income-67.25M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out128.19M

Employees—

ListedFri, Feb 27, 2026

Free float97.95M

Float %76.4%

Short interest7.46M

Days to cover3.7d

Short volume60.3%

Squeeze score55 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.52 vs −$0.48

Last surprise-8.3% miss

Setup gradeD

Conviction31 / 100

Pattern quality—

Tech rank72.9 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance20.32

Support13.56

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GENB

All disclosures →

No recent disclosed trades by Congress in GENB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GENB

No recent insider (Form 4) filings in GENB. Insiders must file within two business days of a trade.

SEC filings

EDGAR filings in GENB · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.